SCHEMBL1442328

SCHEMBL1442328

CCSC(SCC)c1ccc(O)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.57
CYP3A4 P08684 2/20 0.57
NFKB1 P19838 1/20 0.55
BLM P54132 2/20 0.54
PMP22 Q01453 1/20 0.54
BCHE P06276 2/20 0.54
TYR P14679 2/20 0.54
ACHE P22303 2/20 0.54
NPSR1 Q6W5P4 1/20 0.51
SLC22A3 O75751 1/20 0.50
FOS P01100 1/20 0.50
TTR P02766 1/20 0.50
JUN P05412 1/20 0.50
NR3C1 P04150 1/20 0.50
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50
MMP1 P03956 1/20 0.47
MAPK1 P28482 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22808307 0.84 TSHR (0.58) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL6232129 0.81 TSHR (0.57) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL5072122 0.79 BCHE (0.73) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL30491037 0.79 BCHE (0.73) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL29761292 0.77 TSHR (0.77) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL178482 0.77 TSHR (0.62) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL17295977 0.77 TSHR (0.62) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL8082807 0.77 TSHR (0.77) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL20563424 0.76 TSHR (0.65) TSHRCYP3A4NFKB1BLMPMP22
SCHEMBL1595549 0.76 TSHR (0.65) TSHRCYP3A4NFKB1BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
US-20200246573-A1 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS STREETERVILLE CAPITAL, LLC 2020-08-06 US claimed
US-9499587-B2 Gamma-AApeptides with potent and broad-spectrum antimicrobial activity UNIVERSITY OF SOUTH FLORIDA (US) 2016-11-22 US claimed
US-20150274782-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY UNIVERSITY OF SOUTH FLORIDA (US) 2015-10-01 US claimed
WO-2013112548-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY UNIVERSITY OF SOUTH FLORIDA (US) 2013-08-01 WO claimed
EP-4548975-A2 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS Beyond Air Ltd (IL) 2025-05-07 EP disclosed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US disclosed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US disclosed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US disclosed
EP-3655009-B1 NANOPARTICLE COMPOSITIONS YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2023-10-11 EP disclosed
US-11660270-B2 Nanoparticle compositions INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-05-30 US disclosed
WO-2009090648-A2 USE OF ANTIMICROBIAL POLYMERS FOR RE-SENSITIZATION OF MICROORGANISMS UPON EMERGENCE OF RESISTANCE TO ANTI-MICROBIAL AGENTS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2009-07-23 WO disclosed
US-7504381-B2 Antimicrobial agents TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2009-03-17 US disclosed
WO-2008132737-A1 NOVEL ANTIMICROBIAL AGENTS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2008-11-06 WO disclosed
EP-1793837-A2 FATTY ACID MODIFIED POLYLYSINES AS ANTIMICROBIAL AGENTS Technion Research & Development Foundation Limited (IL) 2007-06-13 EP disclosed
US-20070032428-A1 Novel antimicrobial agents TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2007-02-08 US disclosed
US-20060074021-A1 Novel antimicrobial agents TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2006-04-06 US disclosed
WO-2006035431-A2 FATTY ACID MODIFIED POLYLYSINES AS ANTIMICROBIAL AGENTS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074021-A1 Novel antimicrobial agents NOTUM, DAO, SLC11A2 TSHR 3555/4885CYP3A4 2925/4885NFKB1 1533/4885
US-20070032428-A1 Novel antimicrobial agents NOTUM, DAO, SLC11A2 TSHR 3555/4885CYP3A4 2925/4885NFKB1 1533/4885
US-20150274782-A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY ANPEP, DNPEP, ENPEP TSHR 3299/4885CYP3A4 2808/4885NFKB1 2821/4885
US-11660270-B2 Nanoparticle compositions NAPEPLD, PHOSPHO1, LIPA TSHR 4783/4885CYP3A4 2836/4885NFKB1 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.